导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.67% | 2023/4773 |
| 近一周 | -1.48% | 2207/5465 |
| 近一月 | -3.02% | 2105/5421 |
| 近一季 | -5.71% | 2161/5231 |
| 近半年 | -0.54% | 1508/4920 |
| 近一年 | 4.60% | 1832/4394 |
| 近两年 | 56.07% | 1338/2954 |
| 近三年 | 35.77% | 885/2253 |
| 成立以来 | 101.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.11% 3039/4961 |
14.16% 1865/5312 |
- - |
- - |
| 2025 | 21.94% 2009/4813 |
-0.66% 2340/3635 |
1.83% 2102/4076 |
19.86% 2086/4524 |
0.56% 1935/4813 |
| 2024 | 17.01% 739/3463 |
2.67% 733/2808 |
-1.43% 1062/3014 |
17.01% 1291/3129 |
-1.18% 1616/3463 |
| 2023 | -9.50% 1176/2656 |
4.02% 1069/2280 |
-4.70% 1259/2385 |
-2.85% 770/2515 |
-6.02% 1595/2655 |
| 2022 | -18.69% 744/2207 |
-14.66% 981/1919 |
7.64% 443/2016 |
-12.88% 800/2113 |
1.61% 1201/2208 |
| 2021 | 5.89% 531/1822 |
-2.77% 701/1255 |
9.56% 545/1330 |
-2.88% 599/1466 |
2.35% 615/1822 |
| 2020 | 40.84% 299/1250 |
-6.44% 484/1028 |
16.84% 408/1067 |
12.43% 386/1164 |
14.60% 261/1184 |
| 2019 | 40.75% 247/1092 |
26.56% 396/754 |
-0.11% 219/804 |
2.86% 280/850 |
8.24% 334/918 |
| 2018 | -23.98% 311/834 |
- - |
- - |
- - |
-11.61% 324/691 |
| 2017 | 18.98% 202/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.43% 261/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏MSCIA股国际通ETF VS. 长安沪深300非周期A(740101) |